AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $79.8462.

Several research firms have weighed in on ANAB. TD Cowen lowered their price objective on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. HC Wainwright restated a “buy” rating and issued a $95.00 target price on shares of AnaptysBio in a report on Monday, August 24th. Wolfe Research reaffirmed an “outperform” rating and issued a $78.00 target price on shares of AnaptysBio in a research report on Monday. UBS Group lifted their price target on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Finally, Scotiabank lowered AnaptysBio to a “hold” rating and set a $70.00 price target on the stock. in a research report on Tuesday, August 25th.

AnaptysBio Price Performance

ANAB stock opened at $56.80 on Friday. AnaptysBio has a 52-week low of $11.40 and a 52-week high of $72.36. The company’s 50 day simple moving average is $58.18 and its 200-day simple moving average is $59.19. The firm has a market capitalization of $1.68 billion, a P/E ratio of -52.59 and a beta of 0.71.

Hedge Funds Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently bought and sold shares of ANAB. Tema ETFs LLC lifted its position in shares of AnaptysBio by 0.6% in the second quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after purchasing an additional 201 shares in the last quarter. Los Angeles Capital Management LLC grew its position in AnaptysBio by 1.5% during the fourth quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock valued at $732,000 after purchasing an additional 225 shares in the last quarter. Larson Financial Group LLC increased its stake in AnaptysBio by 21.2% in the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 284 shares during the period. Susquehanna Portfolio Strategies LLC increased its stake in AnaptysBio by 1.4% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock valued at $1,743,000 after buying an additional 500 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new position in AnaptysBio in the 2nd quarter valued at approximately $39,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.